Close
  Indian J Med Microbiol
 

Figure 17: Comparison of IL-23 blockers at week 52/48—tildrakizumab (reSURFACE 2) at week 52; guselkumab (VOYAGE 1) at week 48; and risankizumab (UltlMMa 1) at week 52

Figure 17: Comparison of IL-23 blockers at week 52/48—tildrakizumab (reSURFACE 2) at week 52; guselkumab (VOYAGE 1) at week 48; and risankizumab (UltlMMa 1) at week 52